Mink Therapeutics, Inc. Stock Price, News & Analysis

MiNK Therapeutics (NASDAQ: INKT) has received a prestigious NIAID grant to advance its allogeneic iNKT cell therapy platform for preventing and treating graft-versus-host disease in stem cell transplant patients. The company is collaborating with the University of Wisconsin to develop this innovative treatment. The research targets a significant unmet need, as nearly 50% of patients undergoing allogeneic stem cell transplants are at risk for GvHD, a severe immune complication with high mortality rates. The non-dilutive funding validates MiNK's iNKT platform, which uniquely regulates immune responses, promotes tissue repair, and suppresses inflammatory pathways. The collaboration combines MiNK's advanced iNKT manufacturing capabilities with the University of Wisconsin's expertise in transplant immunology.

MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2025 financial results and clinical progress. The company achieved a significant breakthrough with a complete remission in testicular cancer using a single infusion of agenT-797. Clinical trials are advancing, including an active Phase 2 trial in gastric cancer at Memorial Sloan Kettering. The company presented promising data showing agenT-797's effectiveness in PD-1-resistant gastroesophageal cancers. MiNK is pursuing strategic partnerships in oncology, immunology, and engineered cell therapies. Financially, Q1 2025 ended with $3.2 million cash, reduced cash burn to $1.3 million (vs $2.5M in Q1 2024), and a net loss of $2.8 million ($0.70 per share). The company expects NIAID funding for its GvHD program by June 2025.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its first quarter 2025 financial results release for May 15, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update.

Investors can access the conference call via dial-in numbers 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 9822477. A live webcast and replay will be available through the company's investor relations website.

MiNK Therapeutics (NASDAQ: INKT) reported its Q4 and full year 2024 financial results, highlighting progress in developing allogeneic iNKT cell therapies. The company's lead candidate, AgenT-797, showed promising results in cancer treatment and inflammatory lung conditions, with an 80% survival rate in VV ECMO patients versus 10% in hospital controls.

Key developments include a Phase 2 trial in advanced gastric cancer, next-generation PRAME-TCR iNKTs development, and MiNK-215 showing anti-tumor activity in colorectal cancer models. The company secured a research collaboration with Autonomous Therapeutics and raised $5.8M in private financing.

Financial results show a year-end cash balance of $4.6M, reduced cash burn with operations using $9.6M in 2024 compared to $15.8M in 2023. Net loss improved to $10.8M ($2.86 per share) in 2024 from $22.5M ($6.54 per share) in 2023.

MiNK Therapeutics (NASDAQ: INKT), a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies, has scheduled its fourth quarter and full year 2024 financial results release for March 18th, 2025, before market opening.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day, featuring a corporate update and discussion of financial results. Investors can access the call via phone at 646-307-1963 (New York) or 800-715-9871 (USA & Canada) using Conference ID 8023784, or through the company's investor relations website.

MiNK Therapeutics (NASDAQ: INKT) presented new translational data from its ongoing Phase 2 study of allo-iNKTs (agenT-797) at the AACR IO Annual Meeting. The study evaluates agenT-797 in combination with botensilimab and balstilimab (BOT/BAL) in patients with refractory gastroesophageal cancer.

The data demonstrated synergy between allo-iNKT cells, checkpoint inhibitors, and chemotherapy, showing robust immune reactivation in unresponsive tumors. Key findings include significant increases in interferon-gamma levels and enhanced tumor infiltration by T cells and antigen-presenting cells. The study revealed that optimal results were achieved when agenT-797 was administered concurrently with checkpoint inhibitors before chemotherapy.

MiNK's allogeneic manufacturing process can generate billions of donor-derived iNKT cells in a single run, producing thousands of doses for global distribution, potentially reducing costs and improving patient access.

MiNK Therapeutics (NASDAQ: INKT) has announced its return to full compliance with Nasdaq Capital Market listing requirements. The company has successfully met both the minimum bid price and market value requirements for continued listing, resolving previous compliance issues.

MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company maintains a pipeline of native and next-generation engineered iNKT programs, with a platform designed for scalable and reproducible manufacturing for off-the-shelf delivery.

MiNK Therapeutics (NASDAQ: INKT) has been selected to present interim data from its ongoing Phase 2 study at the AACR IO Annual Meeting in Los Angeles. The presentation will focus on their investigation of AgenT-797 in combination with botensilimab and balstilimab (BOT/BAL) for treating refractory gastric cancer patients.

The study specifically targets patients with PD-1 refractory gastroesophageal cancer (GEC) who have received second-line or later treatment. The presentation, scheduled for February 25th, will include biomarker analysis from the trial combining iNKT cell therapy with CTLA-4 and PD-1 inhibitors.

MiNK Therapeutics (NASDAQ: INKT) announced a presentation at the ASCO GI Symposium, highlighting their novel combination therapy approach for advanced gastroesophageal cancers. The company is conducting a Phase 2 trial at Memorial Sloan Kettering Cancer Center, combining agenT-797 (iNKT cells) with botensilimab/balstilimab (BOT/BAL) plus ramucirumab and paclitaxel for previously treated patients.

Previous Phase 1 trial data showed durable responses and tolerability in PD-1 refractory cancers, with gastric cancer patients demonstrating significant clinical and immunologic responses. The company plans to provide a clinical update from the ongoing Phase 2 study in the second half of 2025.

CEO Dr. Jennifer Buell emphasized that iNKT cells play a important role in immune reconstitution, while BOT/BAL enhances T-cell priming and eliminates immunosuppressive regulatory cells, creating a comprehensive approach to make disease biologically unsustainable.